Sensitization of Cancer Cells through Reduction of Total Akt and Downregulation of Salinomycin-Induced pAkt, pGSk3β, pTSC2, and p4EBP1 by Cotreatment with MK-2206
Figure 4
Cotreatment with MK-2206 reduced the levels of p70S6K, mTOR, and PDK1 activated forms and reduced Sal-activated GSk3, TSC2, and 4EBP1. (a–c) Hs578T cell extracts were collected at 24 h after treatment with 0.5 μM MK-2206, 5 μM Sal (Sal), 0.5 μM MK-2206 with 5 μM Sal (MK + Sal), or DMSO (Con). The cells were used for Western blot analyses using antibodies against phosphorylated mTOR, mTOR, phosphorylated p70S6K, phosphorylated PDK1, phosphorylated GSK3, phosphorylated TSC2, phosphorylated 4EBP1, phosphorylated PTEN, PTEN, PI3K, FOXO1, Survivin, Cyclin D1, CDK4, PCNA, pRb, and GAPDH. (d) Hs578T cell extracts were collected at 24 h after treatment with 1 μM MK-2206, 5 μM Sal (Sal), 1 μM MK-2206 with 5 μM Sal (MK-1 + Sal), or DMSO (Con). The cells were used for Western blot analyses using antibodies against phosphorylated mTOR, phosphorylated p70S6K, phosphorylated GSK3, phosphorylated TSC2, phosphorylated 4EBP1, Cyclin D1, pRb, and GAPDH.
